Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience-Reference-Cited by-同舟云学术

Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience

Published:2017-12 Issue:12 Volume:7 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Mediwake Heshani,Curley Cameron,Butler Jason,Mclean Angela,Tey Siok,Hill Geoffrey R.,Morton Anthony,Misra Ashish,Subramoniapillai Elango,Durrant Simon,Kennedy Glen A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-017-0012-0.pdf

Reference15 articles.

1. Nakamae, H. et al. Low-dose total body irradiation and fludarabine conditioning for HLA-Class I mismatched donor stem cell transplantation and immunological recovery in patients with hematological malignancies: a multi-center trial. Biol. Blood. Marrow. Transplant. 16, 384 (2010).

2. Ballen, K. K., Koreth, J., Chen, Y.-B., Dey, B. R. & Spitzer, T. R. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 119, 1972–1980 (2012).

3. Lee, S. J. et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 110, 4576–4583 (2007).

4. Holtan, S. G. et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 125, 1333–1338 (2015).

5. Glucksberg, H. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 18, 295–304 (1974).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic stem cell transplantation for thalassemia major using HLA fully-matched and mismatched donor grafts;Translational Pediatrics;2021-06

2. Myeloablative haploidentical t‐cell replete hematopoietic cell transplantation with post‐transplant cyclophosphamide in high‐risk hematological malignancies: Bending the learning curve in a middle‐income setting;ADVANCES IN CELL AND GENE THERAPY;2021-01-07

3. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT;Journal of Clinical Oncology;2020-06-20